Vytrus Biotech Increases Sales By 28% Until June and EBITDA By 40%

Vytrus Biotech sees double-digit sales growth. The Catalan biotechnology company had a turnover of 2.5 million euros in the first half of 2024, which is 28% more than the 1.9 million recorded until June 2023 , while it obtained a gross operating profit (EBITDA) of almost one million euros, 38% more, the company reported on Tuesday.

Specifically, Vytrus Biotech has indicated that the increase in sales has been led mainly by the recovery of the United States and European markets at the beginning of this year, which have grown by 26% .

Thus, this increase during the first six months of the year has boosted Vytrus Biotech’ year-on-year sales, that is, in the last twelve months, reaching 4.3 million euros for the first time in its history , with solar, sensitive skin and hair applications being the main reasons for the increase in all markets.

Vytrus Biotech anticipates reaching five million EBITDA

On the other hand, the Catalan biotech company has indicated that operating costs rose by 10%, falling below the increase in sales, so these figures boost the biotechnology company’s forecasts. Vytrus Biotech recently published its strategic plan for the period between 2024 and 2027, with which it hopes to triple its sales, reaching twelve million euros, and quadruple its EBITDA, up to five million .

Round of 2.3 million for Vytrus Biotech strategic plan

Last May, the biotechnology company Vytrus Biotech closed a financing round of 2.3 million euros in which it increased and renewed part of its shareholding, with the main objective of financing its strategic expansion plan.

Part of the funds, 1.2 million euros, were raised through a capital increase led by Boyser, a family office linked to one of the founding families of Fluidra, and in which minority shareholders also participated.

Vytrus Biotech also welcomed several institutional investors who together hold around 5% of the capital. The transactions were carried out through the purchase and sale of shares on the block market for an amount close to 1.1 million euros , carried out at the same price as the capital increase.

__

(Featured image by Stock Birken via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us